Accord Paclitaxel Injection

Indication

Treatment of various types of cancer including breast cancer, ovarian cancer, and non-small cell lung cancer.

Dosage (summary)

Administered as an intravenous infusion; typical doses range from 135 mg/m² to 175 mg/m² every 3 weeks, depending on the specific cancer type and treatment regimen.

Onset of Action / Duration

Onset of action varies; effects may be observed within days to weeks after administration, depending on the tumor type and individual response.

Special Populations

• Elderly patients
• Patients with hepatic impairment
• Patients with renal impairment

Pregnancy & Breastfeeding

Paclitaxel is contraindicated in pregnancy and breastfeeding due to potential harm to the fetus or infant.

Key Drug Interactions

• CYP2C8 inhibitors (e.g., gemfibrozil) may increase paclitaxel levels.
• CYP3A4 inducers (e.g., rifampicin) may decrease paclitaxel levels.
• Concurrent use with other myelosuppressive agents may increase the risk of neutropenia.

Contraindications

• Hypersensitivity to paclitaxel or any component of the formulation.
• Severe bone marrow suppression.
• Pregnancy and lactation.

Common side effects

• Neutropenia
• Peripheral neuropathy
• Nausea and vomiting
• Alopecia
• Fatigue
• Hypersensitivity reactions

Counselling Points

• Inform patients about the potential side effects and the importance of reporting any unusual symptoms.
• Advise on the need for regular blood tests to monitor blood cell counts.
• Discuss the importance of contraception during treatment and for a period after treatment.